Bayer reacted strongly to the announcement by Secretary of State for DEFRA, Michael Gove MP today that he will 'in principle' support the European Commission's proposal to ban the use of neonicotinoid seed treatments in non-flowering crops.
Dr Julian Little, a spokesperson for Bayer in the UK, said: "This is a bizarre decision and one that flies in the face of sound science. The Government's own UK Biodiversity Indicators published only this summer show that butterfly, bee and hover fly population numbers have stabilised since 2011 and this was confirmed only earlier this week in response to a Parliamentary question. The suggestion that the extension of this ban to non-flowering crops, which pollinating insects do not visit, will somehow improve the health of bees is farcical.
"We do know from talking to farmers that such a ban would seriously impact the UK's ability to grow high quality wheat, barley, sugar beet and some vegetable crops, just as UK farmers are trying to gear up to life after European subsidies. Farmers will have to resort to older chemical sprays to control damaging insect pests rather than the targeted seed treatments currently employed, and will have to use much larger quantities of slug pellets, just at the time when we are trying to reduce their use.
"Today's decision is therefore a kick in the teeth for UK agriculture: it makes farmers less competitive, it means less environmentally friendly chemicals being used in the countryside, it means no improvement in the lot of bees or other pollinators, and it says to the green lobby that if you make enough noise, you can trump evidence-based policy making.
Note to editors:
More information about Bayer can be found at www.cropscience.bayer.co.uk
Mike Abram Tel: 01223 226621
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.